These distinctions have therapeutic implications: peritoneal forms require stage-targeted approaches (anti-inflammatory in early stages, immunosuppression reversal in advanced); ovarian forms necessitate dual targeting of local and systemic inflammation; adenomyosis demands TLR4 pathway inhibition and Treg restoration; deep infiltrative forms may respond to IDO1/COX-2 blockade and checkpoint inhibitors; extragenital forms require NK cell restoration strategies. This evidence concerns the gene TLR4 and adenomyosis.